InvestorPlace – Stock Market News, Stock Advice & Trading Tips
It’s been a difficult time for biotechnology stocks. After a boom during the Covid-19 pandemic, the entire sector appears to have been abandoned by investors. The Standards and Practices (S&P) 500 Biotechnology Select Industry Index has declined 11% throughout the past 12 months and is down 18% throughout the last five years. Companies large and small have seen their stock prices slump as investor confidence in the industry wanes. Of course, hurdles surrounding prescription drug makers and medical treatments are legendary. Having said that, there are still some undervalued biotech stocks that you should consider.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.